Falcigo 120mg Injection contains artesunate 120 mg, an antimalarial medicine used to treat malaria. Current product information identifies the active ingredient as artesunate and describes administration by a healthcare professional.

What Is Falcigo 120mg Injection?

Falcigo 120mg Injection is a prescription injectable antimalarial containing 120 mg of artesunate. Malaria is a potentially serious parasitic infection transmitted through infected mosquitoes, and severe malaria can become life-threatening without prompt medical treatment. Artesunate acts rapidly against malaria parasites and forms an important part of treatment for severe malaria.

For U.S. practice, FDA-approved artesunate for injection is indicated for the initial treatment of severe malaria in adults and children. Treatment should subsequently transition to a complete course of an appropriate oral antimalarial medicine.

Because the Falcigo 120mg Injection brand is marketed by Zydus Healthcare in India, patients in the United States should verify the product’s regulatory status, sourcing, and suitability with a licensed healthcare professional before obtaining or using it.

How Does Falcigo 120mg Injection Work?

Falcigo 120mg Injection works through artesunate, an artemisinin derivative with rapid antimalarial activity. After administration, artesunate is converted into its active metabolite, dihydroartemisinin. This active compound damages malaria parasites and interferes with their survival inside infected red blood cells.

The rapid action of artesunate makes injectable treatment particularly valuable when malaria is severe or when a patient cannot reliably take oral medicine. FDA prescribing information recommends intravenous artesunate for initial severe-malaria treatment, followed by appropriate oral antimalarial therapy once the patient can take oral medication.

Uses of Falcigo 120mg Injection

Doctors may prescribe Falcigo 120mg Injection as part of treatment for malaria when injectable artesunate is clinically appropriate. Product references describe artesunate 120 mg as an antimalarial used for malaria, while U.S. FDA labeling specifically supports intravenous artesunate for initial treatment of severe malaria.

Severe malaria can involve complications such as impaired consciousness, severe anemia, respiratory problems, kidney injury, or other organ dysfunction. Such patients require urgent medical evaluation and hospital-level care rather than self-treatment.

Importantly, injectable artesunate is not a complete treatment strategy for every malaria infection. After initial parenteral therapy, clinicians generally prescribe an appropriate oral antimalarial regimen. Artesunate also does not eliminate dormant liver-stage parasites responsible for relapse from Plasmodium vivax or Plasmodium ovale; additional treatment may therefore be necessary in appropriate cases.

Related Product

How Is Falcigo 120mg Injection Given?

A healthcare professional should prepare and administer Falcigo 120mg Injection according to the product’s approved instructions and the patient’s clinical condition. Patients should never attempt to reconstitute or inject this medicine themselves.

The exact dose and route depend on the formulation, patient weight, diagnosis, and applicable prescribing information. U.S. FDA-approved artesunate for injection is administered intravenously using a weight-based regimen for severe malaria.

After the patient’s condition improves and oral therapy becomes possible, clinicians complete treatment with an appropriate oral antimalarial. Do not stop treatment simply because fever or other symptoms improve.

Side Effects and Safety

Some patients receiving Falcigo 120mg Injection may experience headache, dizziness, weakness, nausea, vomiting, reduced appetite, or injection-site discomfort. Product information also reports reactions such as pain, swelling, or redness around the injection site.

More serious reactions require prompt medical attention. FDA labeling for artesunate warns about serious hypersensitivity reactions, including anaphylaxis, and post-treatment hemolysis. Hemolytic anemia can occur after treatment, so appropriate monitoring may be necessary for several weeks after therapy.

Seek immediate medical attention for difficulty breathing, facial or throat swelling, severe weakness, unusual paleness, dark urine, yellowing of the skin or eyes, fainting, or other concerning symptoms.

Important Precautions

Before receiving Falcigo 120mg Injection, tell the treating clinician about allergies, pregnancy, breastfeeding, kidney or liver problems, anemia, and all medicines or supplements you currently use.

Drug interactions can affect artesunate treatment. FDA prescribing information specifically identifies certain antiretroviral medicines and strong UGT-inducing medicines as combinations requiring clinical consideration and monitoring.

Pregnancy should not delay lifesaving treatment for severe malaria when artesunate is clinically indicated. However, the treating physician should know about pregnancy before selecting and administering therapy.

Why Proper Medical Supervision Matters

Falcigo 120mg Injection is not an ordinary over-the-counter fever medicine. Malaria can progress quickly, and severe malaria requires rapid diagnosis, appropriate antimalarial therapy, supportive care, and monitoring.

Patients should use Falcigo 120mg Injection only under qualified medical supervision. A healthcare professional determines whether injectable artesunate is appropriate, establishes the treatment schedule, monitors response, and arranges the required follow-up oral therapy.

If you are considering purchasing Falcigo 120mg Injection, use a legitimate, licensed pharmacy and follow applicable prescription and regulatory requirements. Do not purchase an injectable medicine solely because an online listing promises fast results or claims that it can “cure” malaria without medical evaluation.

Frequently Asked Questions

1. What is Falcigo 120mg Injection used for?

Falcigo 120mg Injection contains artesunate and is used as an antimalarial medicine. Injectable artesunate is particularly important for the initial treatment of severe malaria under medical supervision.

2. Can I inject Falcigo 120mg Injection myself?

No. A qualified healthcare professional should prepare and administer this injectable medicine. Self-injection can result in incorrect preparation, dosing, administration, or serious complications.

3. Does Falcigo 120mg Injection completely cure malaria by itself?

Not necessarily. Initial injectable artesunate treatment for severe malaria must be followed by a complete appropriate oral antimalarial regimen. The exact regimen depends on the malaria species and clinical circumstances.

4. What are common side effects?

Reported effects include headache, dizziness, weakness, nausea, vomiting, appetite changes, and injection-site reactions. Serious allergic reactions and delayed hemolysis require medical attention.

5. Can pregnant patients receive artesunate?

Severe malaria can be dangerous to both the pregnant patient and fetus. FDA labeling states that treatment of severe malaria with artesunate should not be delayed because of pregnancy when treatment is medically necessary. The treating clinician should make the treatment decision.